Compare Blackstone Inc (BX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs GSK plc — how do they compare? Blackstone Inc trades at $129.7 (market cap $152.15B), while GSK plc trades at $51.78 (market cap $101.55B). The key difference: Blackstone Inc is the larger of the two by market cap, and Blackstone Inc pays the higher dividend (3.99%). Which is the better fit depends on your goals.
| BX | GSK | |
|---|---|---|
Market Cap | $152.15B | $101.55B |
Sector | Financials | Health |
52-Week High | $188.68 | $61.18 |
52-Week Low | $102.12 | $36.20 |
Dividend Yield | 3.99% | 3.5% |
Enterprise Value | — | $122.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
